避妊薬の米国市場2020-2027:製品別(ピル、コンドーム、膣リング、皮下インプラント、IUD、注射剤)

【英語タイトル】U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product (Pills, Condoms, Vaginal Ring, Subdermal Implants, IUD, Injectable), And Segment Forecasts, 2020 - 2027

Grand View Researchが出版した調査資料(GV21JA098)・商品コード:GV21JA098
・発行会社(調査会社):Grand View Research
・発行日:2020年12月28日
・ページ数:80
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:米国
・産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥618,800見積依頼/購入/質問フォーム
Multi UserUSD6,950 ⇒換算¥722,800見積依頼/購入/質問フォーム
Enterprise UserUSD8,950 ⇒換算¥930,800見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
グランドビューリサーチ社は、避妊薬の米国市場規模が2027年までに100億ドルに達すると予測しています。2020年から2027年までに年平均4.3%成長する見通しです。本市場調査資料では、避妊薬の米国市場を広く調査・分析し、手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、製品別分析、長時間作用型可逆的避妊法(LARC)市場分析、競争分析など、以下の構成でまとめております。
【レポートの概要】

U.S. Contraceptive Market Growth & Trends
The U.S. contraceptive market size is expected to reach USD 10 billion by 2027 registering a CAGR of 4.3%, according to a new report by Grand View Research, Inc. Improving access and awareness regarding Long-Acting Reversible Contraceptives (LARCs) and the effectiveness and convenience of using these products are expected to drive the growth of the market. The Guttmacher Institute reports 60% of women of reproductive age use contraception in the U.S. Use of hormonal contraceptives other than the birth control pill has significantly increased in married women.

Key market players are actively investing in the clinical pipeline, resulting in high competition and an increase in the quality of contraceptives. In January 2019, Mithra Pharmaceuticals announced the success of Estelle’s phase 3 study conducted in the U.S. and Canada, meeting the primary efficacy endpoint. The efficacy was reported to be similar to a recently FDA-approved Annovera & Lo-Loestrin. In August 2019, Agile Therapeutics, Inc. reported that the company is on track to request FDA approval for Twirla. The company is expected to conduct a review with the U.S. FDA’s advisory committee in October 2019 for Twirla’s New Drug Application.

U.S. Contraceptive Market Report Highlights

• The prevalence of teenage pregnancies is highest in the U.S. Government initiatives, such as improving sex education and increasing access to contraceptives, is expected to boost the adoption of various birth control methods in the country

• In 2019, the pills segment held the largest market share owing to the convenience of use and easy availability. The contraceptive pills market in the country is highly competitive due to the presence of generic products

• Intrauterine Devices (IUDs) was also among the major product segments in 2019 and will expand further at a steady CAGR from 2020 to 2027 with increasing demand for hormonal IUDs

• The rapid growth of subdermal implants in the U.S. contraceptive market is anticipated in the coming years. The subdermal implants market is highly consolidated with the presence of very few players

• Key companies in this market are focusing more on M&A and product development to gain a competitive edge over others

• In February 2020, TherapeuticsMD, Inc. entered into an agreement with Afaxys Pharma, LLC to increase access to ANNOVERA in the U.S. public health sector

• In February 2020, Agile Therapeutics, Inc. received FDA approval for the sale of Twirla in the U.S.

【レポートの目次】

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.2 Volume Price Analysis
1.7 List Of Secondary Sources
1.8 List Of Primary Sources
1.9 List Of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.2.1 Product
2.3 Competitive Insights
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rapid Technological Advancements
3.2.1.2 Increasing Initiatives By Social Organizations To Improve Access To Condoms
3.2.1.3 Rising Publicly Funded Family Planning Services
3.2.2 Market Restraint Analysis
3.2.2.1 Increasing Geriatric Population And Rising Prevalance Of Infertility
3.2.2.2 Adverse Effects Associated With Use Of Contraceptive Drugs And Devices
3.3 Business Environment Analysis Tools
3.3.1 Pestle Analysis
3.3.1.1 Political & Legal Landscape
3.3.1.2 Economic & Social Landscape
3.3.1.3 Technological Landscape
3.3.2 Porter’s Five Forces Analysis
3.3.2.1 Competitive Rivalry – High
3.3.2.2 Bargaining Power Of Suppliers – Moderate
3.3.2.3 Bargaining Power Of Buyers – Moderate
3.3.2.4 Threat Of New Entrants – High
3.3.2.5 Threat Of Substitutes – Moderate
3.4 Penetration & Growth Prospect Mapping
3.4.1 Analysis
3.5 Pipeline Analysis
3.6 Regulatory & Reimbursement Framework
3.6.1 Regulatory Scenario
3.6.2 Reimbursement Framework
3.7 Impact Of COVID – 19: Qualitative Analysis
Chapter 4 U.S. Contraceptive Market: Product Analysis
4.1 U.S. Contraceptive Market Share Analysis, 2019 & 2027
4.2 U.S. Contraceptive Product Market: Segment Dashboard
4.3 Market Size & Forecasts And Trend Analysis, 2016 To 2027 For The Product Segment
4.3.1 Pills
4.3.1.1 Pills Market, 2016 – 2027 (USD Million)
4.3.2 Intrauterine Device (IUD)
4.3.2.1 Intrauterine Device Market, 2016 – 2027 (USD Million)
4.3.2.2 Hormonal IUD
4.3.2.2.1 Hormonal IUD Market, 2016 – 2027 (USD Million)
4.3.2.3 Nonhormonal IUD
4.3.2.3.1 Nonhormonal IUD Market, 2016 – 2027 (USD Million)
4.3.3 Condoms
4.3.3.1 Condoms Market, 2016 – 2027 (USD Million)
4.3.4 Vaginal Ring
4.3.4.1 Vaginal Ring Market, 2016 – 2027 (USD Million)
4.3.5 Subdermal Implants
4.3.5.1 Subdermal Implants Market, 2016 – 2027 (USD Million)
4.3.6 Injectable
4.3.6.1 Injectable Market, 2016 – 2027 (USD Million)
4.3.7 Others
4.3.7.1 Others Market, 2016 – 2027 (USD Million)
Chapter 5 U.S. Long Acting Reversible Contraception (LARC) Market
5.1 Penetration Analysis
Chapter 6 Competitive Analysis
6.1 Recent Developments & Impact Analysis, By Key Market Participants
6.2 Strategic Framework/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
6.3 Major Deals & Strategic Alliances Analysis
6.3.1 Mergers & Acquisitions And Joint Ventures
6.3.2 Licensing & Partnership And Technology Collaborations
6.4 Vendor Landscape
6.4.1 List Of Players In U.S. Contraceptive Market
6.4.2 Company Market Position Analysis (Market Presence, Employee Strength, Product Portfolio, Strategic Initiatives)
6.5 Company Profiles
6.5.1 Church & Dwight Co., Inc.
6.5.1.1 Company Overview
6.5.1.2 Financial Performance
6.5.1.3 Product Benchmarking
6.5.1.4 Strategic Initiatives
6.5.1.5 Swot Analysis
6.5.2 Reckitt Benckiser Group Plc
6.5.2.1 Company Overview
6.5.2.2 Financial Performance
6.5.2.3 Product Benchmarking
6.5.2.4 Strategic Initiatives
6.5.2.5 Swot Analysis
6.5.3 Veru, Inc.
6.5.3.1 Company Overview
6.5.3.2 Financial Performance
6.5.3.3 Product Benchmarking
6.5.3.4 Strategic Initiatives
6.5.3.5 Swot Analysis
6.5.4 Merck & Co., Inc.
6.5.4.1 Company Overview
6.5.4.2 Financial Performance
6.5.4.3 Product Benchmarking
6.5.4.4 Strategic Initiative
6.5.4.5 Swot Analysis
6.5.5 Pfizer, Inc.
6.5.5.1 Company Overview
6.5.5.2 Financial Performance
6.5.5.3 Product Benchmarking
6.5.5.4 Strategic Initiatives
6.5.5.5 Swot Analysis
6.5.6 Teva Pharmaceutical Industries Ltd.
6.5.6.1 Company Overview
6.5.6.2 Financial Performance
6.5.6.3 Strategic Initiatives
6.5.6.4 Swot Analysis
6.5.7 The Cooper Companies, Inc.
6.5.7.1 Company Overview
6.5.7.2 Financial Performance
6.5.7.3 Product Benchmarking
6.5.7.4 Strategic Initiative
6.5.7.5 Swot Analysis
6.5.8 Mayer Laboratories, Inc.
6.5.8.1 Company Overview
6.5.8.2 Product Benchmarking
6.5.9 Agile Therapeutics
6.5.9.1 Company Overview
6.5.9.2 Financial Performance
6.5.9.3 Product Benchmarking
6.5.9.4 Strategic Initiatives
6.5.9.5 Swot Analysis
6.5.10 TherapeuticsMD, Inc.
6.5.10.1 Company Overview
6.5.10.2 Financial Performance
6.5.10.3 Product Benchmarking
6.5.10.4 Strategic Initiative
6.5.10.5 Swot Analysis
6.5.11 Allergan
6.5.11.1 Company Overview
6.5.11.2 Financial Performance
6.5.11.3 Product Benchmarking
6.5.11.4 Strategic Initiatives
6.5.11.5 Swot Analysis
6.5.12 Bayer Ag
6.5.12.1 Company Overview
6.5.12.2 Financial Performance
6.5.12.3 Product Benchmarking
6.5.12.4 Strategic Initiatives
6.5.12.5 Swot Analysis
6.5.13 Afaxys, Inc.
6.5.13.1 Company Overview
6.5.13.2 Product Benchmarking
6.5.13.3 Strategic Initiatives
6.5.13.4 Swot Analysis
6.5.14 Mithra Pharmaceuticals
6.5.14.1 Company Overview
6.5.14.2 Financial Performance
6.5.14.3 Product Benchmarking
6.5.14.4 Strategic Initiatives
6.5.14.5 Swot Analysis
6.5.15 Blairex Laboratories, Inc.
6.5.15.1 Company Overview
6.5.15.2 Financial Performance
6.5.15.3 Product Benchmarking
6.5.16 Sebela Pharmaceuticals
6.5.16.1 Company Overview
6.5.16.2 Financial Performance
6.5.16.3 Product Benchmarking
6.5.16.4 Strategic Initiatives
6.5.17 Mona Lisa
6.5.17.1 Company Overview
6.5.17.2 Product Benchmarking
6.5.18 Pregna International Ltd.
6.5.18.1 Company Overview
6.5.18.2 Financial Performance
6.5.18.3 Product Benchmarking
6.5.19 Prosan International B.V.
6.5.19.1 Company Overview
6.5.19.2 Financial Performance
6.5.19.3 Product Benchmarking
6.5.20 SMB Corporation Of India
6.5.20.1 Company Overview
6.5.20.2 Financial Performance
6.5.20.3 Product Benchmarking
6.5.21 Abbvie
6.5.21.1 Company Overview
6.5.21.2 Financial Performance
6.5.21.3 Product Benchmarking
6.5.21.4 Strategic Initiatives
6.5.21.5 Swot Analysis
6.5.22 MELBEA Innovations Ltd.
6.5.22.1 Company Overview
6.5.22.2 Product Benchmarking
6.5.23 DKT International
6.5.23.1 Company Overview
6.5.23.2 Financial Performance
6.5.23.3 Product Benchmarking
6.5.23.4 Strategic Initiatives
6.5.23.5 Swot Analysis
6.5.24 OCON Healthcare
6.5.24.1 Company Overview
6.5.24.2 Product Benchmarking
Chapter 7 Recommendations
7.1 KOL Comments
7.2 Recommendations
Chapter 8 Research Methodology & Scope
8.1 Market Definition
8.1.1 Product
8.2 Research Methodology
8.3 Information Procurement
8.3.1 Purchased Database
8.3.2 GVR’s Internal Database
8.3.3 Secondary Sources
8.3.4 Primary Research
8.4 Information Or Data Analysis
8.4.1 Data Analysis Models
8.5 Market Formulation & Validation
8.6 Model Details
8.6.1 Commodity Flow Analysis
8.6.2 Variable Analysis
8.7 List Of Secondary Sources
8.8 List Of Primary Sources
8.9 List Of Abbreviations
Chapter 9 Report FAQs
9.1 How Do I Trust Your Report Quality/Data Accuracy?
9.2 My Research Requirement Is Very Specific; Can I Customize This Report?
9.3 I Have A Pre-Defined Budget. Can I Buy Chapters/Sections Of This Report?
9.4 How Do You Arrive At These Market Numbers?
9.5 Who Are Your Clients?
9.6 how Will I Receive This Report?
Chapter 10 Appendix
Chapter 11 Compass – Cloud Based Report Delivery Platform
Chapter 12 Related Reports

List of Tables

TABLE 1 List of Secondary Sources
TABLE 2 List of Abbreviation
TABLE 3 U.S. Contraceptive Market, By Product, 2016 - 2027 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Data triangulation techniques
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value-chain-based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Market formulation & validation
FIG. 8 Market outlook, 2019 (USD Million)
FIG. 9 Market trends & outlook
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 The U.S. contraceptive product market share analysis, 2019 & 2027 (USD Million)
FIG. 14 The U.S. contraceptive product market: Segment dashboard
FIG. 15 Pills market, 2016 - 2027 (USD Million)
FIG. 16 Intrauterine device market, 2016 - 2027 (USD Million)
FIG. 17 Hormonal IUD market, 2016 - 2027 (USD Million)
FIG. 18 Nonhormonal IUD market, 2016 - 2027 (USD Million)
FIG. 19 Condoms market, 2016 - 2027 (USD Million)
FIG. 20 Vaginal ring market, 2016 - 2027 (USD Million)
FIG. 21 Subdermal implants market, 2016 - 2027 (USD Million)
FIG. 22 Injectable market, 2016 - 2027 (USD Million)
FIG. 23 Others market, 2016 - 2027 (USD Million)
FIG. 24 U.S. LARC penetration analysis
FIG. 25 Impact analysis by key market participants
FIG. 26 Strategy framework / Competition categorization
FIG. 27 Company market position analysis (Product portfolio, overall revenue, strategic initiatives, market presence)

★調査レポート[避妊薬の米国市場2020-2027:製品別(ピル、コンドーム、膣リング、皮下インプラント、IUD、注射剤)] (コード:GV21JA098)販売に関する免責事項を必ずご確認ください。
★調査レポート[避妊薬の米国市場2020-2027:製品別(ピル、コンドーム、膣リング、皮下インプラント、IUD、注射剤)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆